Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries.

Ku DD, Zaleski JK, Liu S, Brock TA.

Am J Physiol. 1993 Aug;265(2 Pt 2):H586-92.

PMID:
8368362
2.
3.

Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin.

Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM.

Circulation. 1998 Jan 6-13;97(1):99-107.

4.

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2793-800.

5.

Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium.

van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM.

Circulation. 1997 Feb 18;95(4):1030-7.

6.

Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin.

Fujii E, Irie K, Ohba K, Ogawa A, Yoshioka T, Yamakawa M, Muraki T.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):475-80.

PMID:
9349634
7.
8.
9.
10.
11.

Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes.

Shen H, Clauss M, Ryan J, Schmidt AM, Tijburg P, Borden L, Connolly D, Stern D, Kao J.

Blood. 1993 May 15;81(10):2767-73.

14.

Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium.

Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M.

Am J Physiol. 1996 Jan;270(1 Pt 2):H411-5.

PMID:
8769777
15.

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.

Clin Cancer Res. 2000 Mar;6(3):957-65.

16.

Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.

Sioussat TM, Dvorak HF, Brock TA, Senger DR.

Arch Biochem Biophys. 1993 Feb 15;301(1):15-20.

PMID:
8442657
17.

Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor.

Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F.

Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H885-91.

18.

Regulation of vascular endothelial growth factor in cardiac myocytes.

Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA.

Circ Res. 1995 May;76(5):758-66.

20.

Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability.

Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ.

Am J Physiol. 1999 Feb;276(2 Pt 2):H535-42.

Items per page

Supplemental Content

Write to the Help Desk